Influenza is a respiratory disease of major global health concern due to its high mutation rate. Current vaccines often show limited efficacy and fail to induce robust and long-lasting immunity. Furthermore, the continuous emergence of new strains with pandemic potential, underscores the urgent need for more effective vaccines developed under a One Health approach. A promising strategy involves the use of conserved antigens combined with innovative adjuvants to improve the breadth and durability of immune protection. The aim of this study was to evaluate the immunogenicity and protective efficacy of an experimental vaccine based on the influenza nucleoprotein (NP) formulated with oil-based adjuvants widely used in veterinary vaccines, such as Montanides ISA, and a novel combination with the TLR3 agonist Poly(I:C).